ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.97
−0.51%Sep 2, 2026, 12:30 UTC
Allogene Therapeutics announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026.
Source:Aug 13, 2026, 07:34 UTC
Dimensional Fund Advisors LP increased its stake in Allogene Therapeutics, Inc. by 25.5% during the first quarter, acquiring an additional 243,839 shares, according to a 13F filing.
Source:Aug 12, 2026, 23:37 UTC
Allogene Therapeutics, Inc. held its Q2 2026 earnings call on August 12, 2026.
Source:Aug 12, 2026, 22:06 UTC
Allogene Therapeutics announced plans to report initial data from its ALLO-329 autoimmune program by year-end 2026.
Source:Jul 29, 2026, 12:30 UTC
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Allogene Therapeutics' cemacabtagene ansegedleucel (cema-cel) for first-line consolidation therapy in large B-cell lymphoma.
Source:Jul 15, 2026, 12:30 UTC
Allogene Therapeutics announced the publication of Phase 1 results of ALLO-316 in the Journal of Clinical Oncology.
Source: